|

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

RECRUITINGSponsored by Haukeland University Hospital
Actively Recruiting
SponsorHaukeland University Hospital
Started2021-03-15
Est. completion2025-12
Eligibility
Age18 Years – 60 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06663111

Summary

ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.

Eligibility

Age: 18 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* Included in OVERLORD-MS (NCT04578639)
* Willing to attend laboratory for blood sample collection at scheduled time points

Exclusion criteria:

\* Not willing to attend laboratory for blood sample collection at scheduled time points

Conditions2

Multiple SclerosisRelapsing Remitting Multiple Sclerosis

Browse More Trials

Multiple Sclerosis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.